SYNEURX INTERNATIONAL TAIWAN CORP.
SyneuRx is a mental health care company that is developing potential treatments for schizophrenia, dementia, and depression. They offer treatment for schizophrenia, depression, and dementia.
SYNEURX INTERNATIONAL TAIWAN CORP.
Industry:
Biopharma Clinical Trials Pharmaceutical
Founded:
2013-01-01
Address:
Taipei, T'ai-pei, Taiwan
Country:
Taiwan
Website Url:
http://www.syneurx.com
Total Employee:
1+
Status:
Active
Contact:
886-2-7742-2699
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics SSL By Default Global Site Tag
Similar Organizations
Arcus Biosciences
Arcus Biosciences is a biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.
Ascentage Pharma
Ascentage is a clinical-stage biopharmaceutical company that develops drugs for the treatment of cancer.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Oppilan Pharma
Oppilan Pharma is a biopharmaceutical company that develops novel small molecule therapeutics for the treatment of autoimmune diseases.
Halo Labs
Halo Labs is a biotechnology company that specializes in analytical instrumentation and biopharma.
PRD Therapeutics
PRD Therapeutics is a pharmaceutical company that develops medicines for different metabolic diseases.
Tanvex BioPharma
Tanvex BioPharma is a biopharmaceutical company that provides drug manufacturing, sales, and distribution services.
Investors List
Taiwania Capital Management Corporation
Taiwania Capital Management Corporation investment in Post-IPO Equity - SyneuRx International Taiwan Corp.
Official Site Inspections
http://www.syneurx.com
- Host name: h117-203-67-103.seed.net.tw
- IP address: 203.67.103.117
- Location: Taiwan
- Latitude: 23.5
- Longitude: 121
- Timezone: Asia/Taipei
More informations about "SyneuRx International Taiwan Corp."
SyneuRx
Nov 18, 2022 SyneuRx is currently conducting clinical development of two COVID-19 treatments— Pentarlandir® in oral capsule form and Airnecflu® in an inhaled form. Pentarlandir® completed US Phase 2 clinical trial in June 2022 …See details»
Draft-About2 – SyneuRx
Vivian Y. Wu, Ph.D, MS, As chief strategy officer, Dr. Wu is SyneuRx’s regulatory contact with the FDA, manages clinical trials, and develops business and strategic activities for SyneuRx outside of Taiwan.Prior to joining SyneuRx, Wu served as an assistant professor at the University of …See details»
SyneuRx Company Profile | Management and Employees List
Prior to starting SyneuRx, Dr. Guochuan (Emil) Tsai, MD, PhD was a member of the faculty at Harvard Medical School and is now at the UCLA School of Medicine, Department of Psychi atry and Biobehavioral Sciences. SyneurRx and Pentarlandir are trademarks and registered …See details»
SyneuRx International (Taiwan) Corp. - Drug pipelines, Patents ...
SyneuRx International (Taiwan) Corp. is involved in the production and distribution of various types of medication. These medicines are primarily utilized for treating brain disorders such as schizophrenia, and mental illnesses such as depression, obsessive compulsive disorder, …See details»
SyneuRx - Company Profile - Tracxn
Nov 27, 2024 SyneuRx, founded by Taiwanese/Americans is developing a novel class of drugs to treat CNS disorders and has offices both in the US and Greater China region. Two of the company's candidates which have been awarded the breakthrough designation are SND 12, a …See details»
SyneuRx - Overview, News & Similar companies | ZoomInfo.com
SyneuRx was founded in 2013 with the goal of using scientific breakthroughs to develop novel CNS drugs for patients suffering from severe mental health disorders. The multi-national team is located in the U.S. and Taiwan. Prior to starting SyneuRx, Dr. Guochuan (Emil) Tsai, MD, PhD …See details»
SyneuRx International - Craft
Jan 26, 2024 SyneuRx International NT$1.32 m in annual revenue in FY 2023. See insights on SyneuRx International including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
SyneuRx CEO Dr. Emil Tsai Exclusive Interview with …
Sep 2, 2022 SyneuRx was founded in 2013 to bring change-making pharmaceuticals to market with a strong, promising pipeline of seven investigational drugs for central nervous system (CNS) disorders and two for …See details»
What we do - SyneuRx
SyneuRx is investigating novel therapies for these unmet medical needs. When successfully developed with the research trials, SyneuRx’ investigational therapy will provide those with mental disorders different treatment options. 20F-10, No.99, Sec.1, Xintai 5th Road, Xizhi Dist. New …See details»
SyneuRx - Products, Competitors, Financials, Employees, …
About SyneuRx. SyneuRx (TWO: 6575) operates as a bio-medical company. It develops medical solutions for the treatment of central nervous system-related disorders including schizophrenia, depression, dementia, and suicidal symptoms. The company was founded in 2013 and is …See details»
SyneuRx International Taiwan Corp. - Crunchbase
Organization. SyneuRx International Taiwan Corp. Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... SyneuRx is a mental health care company that is developing potential treatments for schizophrenia, …See details»
SyneuRx Corp Overview - Salary.com
SyneuRx Corp Information BETA. Headquarters Address: 7700 Irvine Center Dr Ste 800, Irvine, California. Phone Number: +886 226972629. Revenue: $5 Million - $10 Million ... The trusted data and intuitive software your organization needs to get pay right.See details»
SyneuRx Neuroscience - Crunchbase Company Profile & Funding
SyneuRx Neuroscience is new drug development. is a global CRO and consultation firm that engages in activities related to the biopharmaceutical industry. Their services are new drug development, clinical trial development, drug manufacturing consultation, and business …See details»
Jeffrey Lu - Independent Director. Chair, Audit Committee
· Mr. Lu serves entrepreneurs and provides transaction advisory for more than three decades. His career started at Peat Marwick Mitchell (KPMG). Mr. Lu developed strong negotiation skills while ...See details»
SyneuRx Neuroscience - Overview, News & Similar companies
Who is SyneuRx Neuroscience. The services SyneuRx Neuroscience provides: 1New Drug Development 1) Evaluation of novel target and/or new drug candidate 2) Patent portfolio and development strategy 3) Gap analysis 2Clinical Trial Development 1) IND enabling 2) Clinical …See details»
Adult Schizophrenia - SyneuRx
You can contact 866-971-0917 to speak to one of the study staff about the study, eligibility to participate, site referrals, etc.See details»
Press Release_List – SyneuRx
Jun 23, 2021 SyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants. Nov 19, 2021. SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir Has …See details»
Research - SyneuRx
SyneuRx is conducting novel drug development research in two major platforms. Antiviral Platform. Read More. NMDA Platform. Read More. Pipeline. A rapidly expanding pipeline of late-phase clinical trials. COVID-19. Preclinical. Phase 1. Phase 2. Phase 3. NDA. Pentarlandir. …See details»
Newsroom – SyneuRx
Jan 6, 2022 Forbes. Dr. Tsai was interviewed and shared his commentary regarding the polio. "No polio cases have been caused by wild poliovirus originating in the U.S. since 1979 until recently when poliovirus was confirmed in an unvaccinated, [healthy] adult resident of New …See details»